Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications-Reference-Cited by-同舟云学术

Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications

Published:2014-10 Issue: Volume:75 Page:199-205
ISSN:0022-2828
Container-title:Journal of Molecular and Cellular Cardiology
language:en
Short-container-title:Journal of Molecular and Cellular Cardiology

Author:

Ichiki Tomoko,Schirger John A.,Huntley Brenda K.,Brozovich Frank V.,Maleszewski Joseph J.,Sandberg Sharon M.,Sangaralingham S. Jeson,Park Soon J.,Burnett John C.

Funder

National Institute of Health

American Heart Association

Mayo Foundation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Molecular Biology

Reference32 articles.

1. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications;Potter;Handb Exp Pharmacol,2009

2. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors;Huntley;J Cell Physiol,2006

3. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction;Soeki;J Am Coll Cardiol,2005